METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY
Objective: Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity and metabolic syndrome (MS). Liver biopsy can verify the histological form of NAFLD. The aim of the study was to evaluate the relationship between histological indicators of liver damage and metabolic parameters....
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Bulgarian Association of Young Surgeons
2018-10-01
|
Series: | International Journal of Surgery and Medicine |
Subjects: | |
Online Access: | http://www.ejos.org/index.php?fulltxt=357 |
id |
doaj-57f699fe99a94e1da174a01e0250c2bf |
---|---|
record_format |
Article |
spelling |
doaj-57f699fe99a94e1da174a01e0250c2bf2021-04-03T16:27:17ZengBulgarian Association of Young SurgeonsInternational Journal of Surgery and Medicine2367-699X2367-699X2018-10-0144http://dx.doi.org/10.5455/ijsm.Risk-factors-in-various-forms-of-NAFLDMETABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITYKsenya KomshilovaNatalya MazurinaEkaterina TrosinaTeona ShvangiradzePavel BogomolovGalina MelnichenkoIvan DedovObjective: Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity and metabolic syndrome (MS). Liver biopsy can verify the histological form of NAFLD. The aim of the study was to evaluate the relationship between histological indicators of liver damage and metabolic parameters. Material and methods: 80 patients, median age 45 [41.5; 47.5], with abdominal obesity and US signs of NAFLD were included in the study. All patients underwent percutaneous liver biopsy. Glucose levels during OGTT, total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides (TG), ALT, and AST were measured. Fasting insulin, serum adiponectin, C-reactive protein (CRP) and active plasminogen antigen activator inhibitor-1 (PAI-1) were determined. Results: NAFLD was confirmed in 77 patients (96.3%), NASH – in 64 cases (80%), steatosis - in 11 cases (13.8%). In patients with steatosis, 72.7% had dyslipidemia, 63.6% had impaired glucose metabolism, 63.6% had insulin resistance (IR); with NASH – in 93.8%, 78.1% and 100%, respectively. Adiponectin level correlated negatively with IR indicators: HOMA-IR (r = - 0.45; p = 0.023) and fasting insulin (r = - 0.35; p = 0.024). NASH patients had significantly higher levels of CRP than those with steatosis: 3.8 [2.1; 6.7] mg/L vs 1,1 [1.0; 1.7] mg/L, (p <0.0001). PAI-1 activity correlated positively with anthropometric parameters, IR, the level of CRP, and negatively with adiponectin concentration. Conclusion: Metabolic disorders in patients with NAFLD are dependent upon the severity of the liver damage and the morphological stage of the disease.http://www.ejos.org/index.php?fulltxt=357nonalcoholic fatty liver diseaseliver biopsyabdominal obesitycardiovascular risk factorstype 2 diabetes mellitus risk factors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ksenya Komshilova Natalya Mazurina Ekaterina Trosina Teona Shvangiradze Pavel Bogomolov Galina Melnichenko Ivan Dedov |
spellingShingle |
Ksenya Komshilova Natalya Mazurina Ekaterina Trosina Teona Shvangiradze Pavel Bogomolov Galina Melnichenko Ivan Dedov METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY International Journal of Surgery and Medicine nonalcoholic fatty liver disease liver biopsy abdominal obesity cardiovascular risk factors type 2 diabetes mellitus risk factors |
author_facet |
Ksenya Komshilova Natalya Mazurina Ekaterina Trosina Teona Shvangiradze Pavel Bogomolov Galina Melnichenko Ivan Dedov |
author_sort |
Ksenya Komshilova |
title |
METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY |
title_short |
METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY |
title_full |
METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY |
title_fullStr |
METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY |
title_full_unstemmed |
METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY |
title_sort |
metabolic markers of cardiovascular disease and type 2 diabetes mellitus in various clinical and morphological forms of nonalcoholic fatty liver disease in patients with abdominal obesity |
publisher |
Bulgarian Association of Young Surgeons |
series |
International Journal of Surgery and Medicine |
issn |
2367-699X 2367-699X |
publishDate |
2018-10-01 |
description |
Objective: Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity and metabolic syndrome (MS). Liver biopsy can verify the histological form of NAFLD. The aim of the study was to evaluate the relationship between histological indicators of liver damage and metabolic parameters.
Material and methods: 80 patients, median age 45 [41.5; 47.5], with abdominal obesity and US signs of NAFLD were included in the study. All patients underwent percutaneous liver biopsy. Glucose levels during OGTT, total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides (TG), ALT, and AST were measured. Fasting insulin, serum adiponectin, C-reactive protein (CRP) and active plasminogen antigen activator inhibitor-1 (PAI-1) were determined.
Results: NAFLD was confirmed in 77 patients (96.3%), NASH – in 64 cases (80%), steatosis - in 11 cases (13.8%). In patients with steatosis, 72.7% had dyslipidemia, 63.6% had impaired glucose metabolism, 63.6% had insulin resistance (IR); with NASH – in 93.8%, 78.1% and 100%, respectively. Adiponectin level correlated negatively with IR indicators: HOMA-IR (r = - 0.45; p = 0.023) and fasting insulin (r = - 0.35; p = 0.024). NASH patients had significantly higher levels of CRP than those with steatosis: 3.8 [2.1; 6.7] mg/L vs 1,1 [1.0; 1.7] mg/L, (p <0.0001). PAI-1 activity correlated positively with anthropometric parameters, IR, the level of CRP, and negatively with adiponectin concentration.
Conclusion: Metabolic disorders in patients with NAFLD are dependent upon the severity of the liver damage and the morphological stage of the disease. |
topic |
nonalcoholic fatty liver disease liver biopsy abdominal obesity cardiovascular risk factors type 2 diabetes mellitus risk factors |
url |
http://www.ejos.org/index.php?fulltxt=357 |
work_keys_str_mv |
AT ksenyakomshilova metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity AT natalyamazurina metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity AT ekaterinatrosina metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity AT teonashvangiradze metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity AT pavelbogomolov metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity AT galinamelnichenko metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity AT ivandedov metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity |
_version_ |
1721543815036141568 |